• Roche gets FDA’s accelerated approval to Tecentriq for TNBC biospectrumasia
    March 12, 2019
    Roche has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) f
PharmaSources Customer Service